Results 161 to 170 of about 103,677 (295)

The effect of PEGylation on surface tethering of liposomes via DNA nanotechnology. [PDF]

open access: yesJ Lipid Res
Gaston JP   +7 more
europepmc   +1 more source

DNA Nanoflower LYTACs Enable Efficient VEGF Degradation and Verteporfin Loading for Combined Therapy of Wet Age‐Related Macular Degeneration

open access: yesAdvanced Science, EarlyView.
An integrated approach that combines a DNA nanoflower VEGF degrader with photodynamic therapy is developed for the treatment of wet age‐related macular degeneration, which reduces the risk of VEGF reactivation‐induced CNV recurrence and minimizes the systemic side effects associated with photodynamic therapy.
Mengxuan Li   +11 more
wiley   +1 more source

A synthetic cell phage cycle. [PDF]

open access: yesNat Commun
Levrier A   +6 more
europepmc   +1 more source

Stimuli‐Responsive Supramolecular Biomaterials for Cancer Theranostics

open access: yesAdvanced Science, EarlyView.
The ultimate goal of cancer theranostics is to get imaging agents and therapeutic cargo to tumor sites when and where they are required. “Smart” systems should be developed. This review discusses the characteristics of physiological stimuli, types and action modes of external stimuli, construction approaches and working principles, as well as ...
Wenting Hu   +4 more
wiley   +1 more source

A Lecithin Liposome Stimulates Soil Microbial Respiration and Nitrate Immobilization. [PDF]

open access: yesACS Agric Sci Technol
Butkus CR   +7 more
europepmc   +1 more source

Neuroprotective Nanoplatform Integrating Antioxidant MXene Nanozymes and Ferroptosis Inhibitors for Targeted Therapy of Cerebral Ischemia‐Reperfusion Injury

open access: yesAdvanced Science, EarlyView.
Cerebral ischemia‐reperfusion injury (CIRI) is a key pathological process limiting the efficacy of stroke therapy. This study has developed an innovative, multifunctional, brain‐targeted nanoplatform (RFP) containing MXene nanoenzymes and ferroptosis inhibitors.
Lu Wang   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy